Modality
ASO
MOA
SGLT2i
Target
BET
Pathway
Checkpoint
LGS
Development Pipeline
Preclinical
~Oct 2012
→ ~Jan 2014
Phase 1
~Apr 2014
→ ~Jul 2015
Phase 2
~Oct 2015
→ ~Jan 2017
Phase 3
Apr 2017
→ Apr 2026
Phase 3Current
NCT07948041
2,547 pts·LGS
2021-03→2026-04·Completed
NCT04813293
1,714 pts·LGS
2017-04→TBD·Completed
4,261 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-04-254w awayPh3 Readout· LGS
2026-04-274w awayNDA· LGS
Trial Timeline
Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P3
Complet…
P3
Complet…
Catalysts
Ph3 Readout
2026-04-25 · 4w away
LGS
NDA
2026-04-27 · 4w away
LGS
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07948041 | Phase 3 | LGS | Completed | 2547 | VA |
| NCT04813293 | Phase 3 | LGS | Completed | 1714 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| JNJ-8232 | Johnson & Johnson | NDA/BLA | MALT1 | |
| RHH-1969 | Roche | Approved | BET | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Bemalucimab | Bristol-Myers Squibb | Phase 1/2 | Aβ | |
| BAY-3308 | Bayer | Phase 1 | ALK | |
| MRN-8225 | Moderna | Preclinical | TNFα | |
| Motazanubrutinib | Biogen | Preclinical | CD38 | |
| ALN-5628 | Alnylam | Phase 1/2 | APOC3 |